TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8707991
Drug: Basic oral
Normalized name: sodium phosphate, dibasic Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic oral hygiene instructions
Study: 25679310
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy combined with two cycles of concomitant cisplatin
Study: 25679310
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy alone
Study: 23102241
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (group A, n = 261)
Study: 17907485
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with Clearfil New Bond adhesive
Study: 10753983
Drug: Warfarin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (2 mg)
Study: 10753983
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1 mg warfarin plus 300 mg aspirin
Study: 10753983
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 mg warfarin plus 300 mg aspirin
Study: 30813694
Drug: Butylphthalide treatment
Normalized name: Butylphthalide
DrugBank: Butylphthalide (DB12749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylphthalide treatment group
Study: 22514730
Drug: Sulfadoxine‐pyrimethamine (SP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (SP) administered early (4 months of gestation)
Study: 22514730
Drug: Sulfadoxine‐pyrimethamine (SP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine‐pyrimethamine (SP) administered late (6-7 months of gestation)
Study: 12766522
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (e.g., amiodarone)
Study: 10667832
Drug: Dexibuprofen 200
Normalized name: ibuprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen 200 mg t.i.d.
Study: 3906995
Drug: D-penicillamine (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (large and mean doses)
Study: 3906995
Drug: Nonsteroidal antiinflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal antiinflammatory drugs (NAID)
Study: 30578651
Drug: inspiratory resistance
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: inspiratory resistance (RES) of ∼5 cmH2O L−1 s−1
Study: 24812899
Drug: Ningdong Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningdong Granule (NG), one dose daily for 3 months, dissolved in boiled water, taken in two portions in the morning and evening.
Study: 24812899
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with NG and Tiapride, equal doses for 3 months.
Study: 24812899
Drug: Tiapride Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride Tablet, 50-100 mg twice daily for 3 months, max dosage 300 mg per day.
Study: 18204271
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro (LPI)
Study: 18204271
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (RGI)
Study: 11379380
Drug: Continuous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous estradiol 50 micrograms/24 h with vaginal progesterone gel 8 mg every 2nd day
Study: 11379380
Drug: Continuous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous estradiol 50 micrograms/24 h with medroxyprogesterone acetate 5 mg/day orally during 12 days per month
Study: 9404445
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (250 mg testosterone enanthate/month for four months)
Study: 25049329
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) followed by chemoradiotherapy (CRT) - docetaxel 75 mg/m² on day 1, cisplatin 75 mg/m² on day 1, fluorouracil 750 mg/m² on days 1 to 5, followed by CRT (docetaxel, fluorouracil, hydroxyurea plus radiotherapy 0.15 Gy twice per day every other week)
Study: 25049329
Drug: Chemoradiotherapy (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (CRT) alone - docetaxel, fluorouracil, and hydroxyurea plus radiotherapy 0.15 Gy twice per day every other week
Study: 20083373
Drug: Paracetamol (acetaminophen)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (acetaminophen) 4 g daily
Study: 19226897
Drug: Visceral differentiation-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visceral differentiation-based acupuncture therapy
Study: 7489976
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (12 g daily for 2 months)
Study: 7489976
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (12 g daily for 2 months)
Study: 30904595
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 mg PRN
Study: 25127405
Drug: NRT (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRT (15 mg/16 h transdermal patches)
Study: 16050054
Drug: Omega-3 FA
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 FA + policosanol 5 mg/day
Study: 16050054
Drug: Omega-3 FA
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 FA + policosanol 10 mg/day
Study: 14624217
Drug: Other coagulation
Normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other coagulation modulators
Study: 11221091
Drug: ROM plus
Normalized name: Ascorbic Acid/Biotin/Boron/Calcium/Calcium Pantothenate/Chloride/Chromium/Copper/Cyanocobalamin/Folic Acid/Iodine/Iron/Lutein/Magnesium/Manganese/Molybdenum/Niacin/Nickel/Phosphorus/Phytonadione/Potassium/Pyridoxine/Riboflavin/Selenium/Silicon Dioxide/Thiamine/Tin/Vanadium/Vitamin A/Vitamin D/Vitamin E/Zinc 60 MG-0.03 MG-0.15 MG-162 MG-10 MG-72 MG-0.12 MG-2 MG-0.006 MG-0.4 MG-0.15 MG-18 MG-0.25 MG-100 MG-2 MG-0.075 MG-20 MG-0.005 MG-109 MG-0.025 MG-80 MG-2 MG-1.7 MG-0.02 MG-2 MG-1.5 MG-0.01 MG-0.01 MG-5000 IU-400 IU-30 IU-15 MG Oral Tablet [VANTROM PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROM plus low-dose Convit vaccine
Study: 11221091
Drug: Single-dose ROM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose ROM therapy
Study: 8971431
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg controlled-release (CR) oxycodone tablets
Study: 8971431
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg immediate-release (IR) oxycodone oral solution
Study: 1732652
Drug: 720 mL/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mL/d of caffeinated coffee
Study: 23823716
Drug: Cocoa product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa product rich in fibre (15 g each, 2 servings daily for 4 weeks)
Study: 22167566
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with 25 mg preladenant
Study: 22167566
Drug: Fasting with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting with 25 mg preladenant
Study: 20018913
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment using intermittent ATRA
Study: 20018913
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment using continuous 6 mercaptopurine plus methotrexate
Study: 20018913
Drug: Both maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both maintenance treatments
Study: 15801944
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg in males with renal impairment
Study: 15801944
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg in healthy males
Study: 12162932
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (lovastatin, pravastatin, simvastatin)
Study: 9602956
Drug: 300-mg irbesartan
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg irbesartan tablet under fasted conditions
Study: 9602956
Drug: 300-mg irbesartan
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg irbesartan tablet 5 minutes after a high-fat breakfast
Study: 29542371
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketamine
Study: 29542371
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg midazolam
Study: 26902307
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg single-dose albendazole administration
Study: 26902307
Drug: 60000 μg
Normalized name: penicillin G potassium 60000 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60000 μg vitamin A capsule combined with 400 mg single-dose albendazole
Study: 22316635
Drug: Pardoprunox (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pardoprunox (up to 42 mg/day)
Study: 20110117
Drug: 8 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 IU/kg of botulinum toxin A injected into the detrusor muscle and 2 IU/kg through 4 injections in external urethral sphincter (Group B)
Study: 9862558
Drug: Phenelzine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenelzine therapy
Study: 9862558
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo administration
Study: 9862558
Drug: Educational-supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational-supportive group therapy
Study: 7695309
Drug: Rufloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 400 mg single dose
Study: 7695309
Drug: Pefloxacin 800
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pefloxacin 800 mg single dose
Study: 827989
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic administration
Study: 827989
Drug: Postoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotic administration
Study: 31611038
Drug: tesamorelin 2
Normalized name: tesamorelin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesamorelin 2 mg once daily for 12 months
Study: 31611038
Drug: placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily for 12 months
Study: 31611038
Drug: tesamorelin 2
Normalized name: tesamorelin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesamorelin 2 mg once daily
Study: 29053120
Drug: Divaza (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divaza (2 tablets 3 times a day)
Study: 26323041
Drug: Dopamine (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (5-10 μg/kg/min)
Study: 26323041
Drug: Epinephrine (0.1-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.1-0.3 μg/kg/min)
Study: 24292818
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (IFF; 0.8-1.0 mg iron/100 ml)
Study: 3289769
Drug: Patient-Controlled Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Epidural Analgesia (PCEA) - Group A (n = 14) received a background infusion of 4 ml/hr 0.125% bupivacaine, with self-administered 4 ml aliquots as required (up to 16 ml/hr).
Study: 3289769
Drug: Continuous Infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Infusion Epidural Analgesia (CIEA) - Group B (n = 11) received a continuous infusion of 12 ml/hr with the demand-button deactivated.
Study: 21938889
Drug: Traditional Occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Occupational Therapy (TOT)
Study: 17122578
Drug: 250 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml Hemospan
Study: 17122578
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml Hemospan
Study: 15322325
Drug: Combined formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined formula consisting of ACEI, AIIRA, CCB, antiplatelet+/−heparin
Study: 10585174
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (NETA; 0.5 mg) alone
Study: 10585174
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (NETA; 0.5 mg) in combination with estradiol (E2; 1 mg)
Study: 10585174
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5 mg NETA with 1 mg E2 administered daily for 28 days
Study: 8901825
Drug: Ramipril and
Normalized name: ramipril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril and felodipine treatment for 6 months
Study: 8901825
Drug: Drug washout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug washout after treatment
Study: 18235123
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of muramyl tripeptide (MTP) to chemotherapy
Study: 18235123
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without MTP
Study: 18235123
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of ifosfamide to chemotherapy
Study: 10374198
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving thrombolytic agents)
Study: 8911009
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.)
Study: 8911009
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.)
Study: 31925799
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral oestradiol-17β 2 mg plus norethisterone acetate 1 mg daily (E2/NETA)
Study: 29453467
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose magnesium sulfate
Study: 29453467
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose only magnesium sulfate
Study: 20726625
Drug: SABA (short-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA (short-acting beta-agonists)
Study: 20726625
Drug: Leukotriene receptor
Normalized name: Leukotriene receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene receptor antagonists (LTRA)
Study: 20726625
Drug: Daily LABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily LABA (salmeterol)
Study: 20726625
Drug: Daily SABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SABA
Study: 18029469
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d rosuvastatin
Study: 7907950
Drug: Taxotere (docetaxel)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere (docetaxel) intravenous infusion at doses of 70-115 mg/m2 every 3 weeks
Study: 7907950
Drug: Taxotere (docetaxel)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taxotere (docetaxel) intravenous infusion
Study: 3002163
Drug: High fiber
Normalized name: High Fiber Gummies Soft Chew
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fiber diet (27 g/1000 kcal)
Study: 3002163
Drug: Normal fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal fiber diet (11 g/1000 kcal)
Study: 23442391
Drug: Probiotics capsules
Normalized name: Culturelle Probiotics Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics capsules containing > 1x10(9) cfu each of Lactobacillus rhamnosus GG and Bifidobacterium lactis BB‐12 per capsule, administered from 16 weeks gestation until delivery.
Study: 23442391
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, administered from 16 weeks gestation until delivery.
Study: 19114190
Drug: Special acupuncture
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special acupuncture technique (preoperative implantation of small intradermal needles retained for 4 weeks)
Study: 17136231
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of ibuprofen on the first day of life
Study: 17136231
Drug: Therapeutic administration
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic administration of ibuprofen to induce closure of a symptomatic PDA
Study: 7826833
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose metoclopramide (7 mg kg‐1 day‐1)
Study: 7826833
Drug: Alizapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (5 mg kg‐1 day‐1)
Study: 21926189
Drug: Tailored cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored cognitive-behavioural therapy and exercise training (16 twice-weekly sessions)
Study: 17209739
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of kinship information from two halves of the face
Study: 12850126
Drug: Levodropropizine 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodropropizine 6% drops administered orally t.i.d. for 10 consecutive administrations
Study: 1555693
Drug: Short regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short regimen of gonadotropin-releasing hormone agonist
Study: 1555693
Drug: Long regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long regimen of gonadotropin-releasing hormone agonist
Study: 22370698
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg oral melatonin daily for 4 months
Study: 20822027
Drug: Rocephin 2
Normalized name: Rocephin 2g Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocephin 2 g once daily for 7 days
Study: 10430393
Drug: Hypoxic upper
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic upper abdominal chemotherapy (Mitomycin‐C, 5‐Fluorouracil, Leucovorin, Farmorubicin) plus systemic chemotherapy
Study: 10430393
Drug: Hypoxic upper
Normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoxic upper abdominal chemotherapy (Mitomycin‐C, 5‐Fluorouracil, Leucovorin, Farmorubicin) without systemic chemotherapy
Study: 10430393
Drug: No neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neo or adjuvant treatment
Study: 7571220
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg/day for 3 months (after a 3-week titration period)
Study: 7571220
Drug: Doxazosin 8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 8 mg/day for 3 months (after a 3-week titration period)
Study: 7571220
Drug: Doxazosin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin administered in the morning or evening
Study: 2076734
Drug: Co-dergocrine mesylate
Normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-dergocrine mesylate (Cod) 4 mg followed by Nifedipine (Nif) 20 mg
Study: 2076734
Drug: Nifedipine (Nif)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Nif) 20 mg with placebo as premedication
Study: 2076734
Drug: Nifedipine (Nif)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Nif) 20 mg with Cod as premedication
Study: 2076734
Drug: Nifedipine (Nif)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Nif) 20 mg
Study: 495541
Drug: Thiamin intake
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamin intake of 0.30 mg per 1000 kcal (derived from carbohydrate sources)
Study: 495541
Drug: Thiamin intake
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamin intake of 0.40 mg per 1000 kcal (recommended by FAO/WHO)
Study: 495541
Drug: Thiamin intake
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamin intake of 0.5 mg per 1000 kcal (recommended by Food and Nutrition Board of NAS‐NRC)
Study: 495541
Drug: Erythrocyte transketolase
Normalized name: erythrocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythrocyte transketolase activity and urinary excretion of thiamin
Study: 31480045
Drug: Pantoprazole (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (intravenously once daily during ICU stay, until ICU discharge, death, or a maximum of 90 days)
Study: 31480045
Drug: Placebo (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenously once daily during ICU stay, until ICU discharge, death, or a maximum of 90 days)